Antiviral therapy improves overall survival in hepatitis C virus‐infected patients who develop diffuse large B‐cell lymphoma

Jeff Hosry(The University of Texas MD Anderson Cancer Center), Harrys A. Torres(The University of Texas MD Anderson Cancer Center), Bruno Granwehr(The University of Texas MD Anderson Cancer Center), Parag Mahale(National Cancer Institute), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Minas P. Economides(NYU Langone Health), Francesco Turturro(The University of Texas MD Anderson Cancer Center)
International Journal of Cancer
August 8, 2016
10.1002/ijc.30372
Cited by 57

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|390
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
|British Journal of Haematology|2014|364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263